Country: Аустралија
Језик: Енглески
Извор: Department of Health (Therapeutic Goods Administration)
dibasic sodium phosphate dodecahydrate, Quantity: 192 mg/mL; monobasic potassium phosphate, Quantity: 17.4 mg/mL
Pfizer Australia Pty Ltd
Injection, concentrated
Excipient Ingredients: water for injections
Intravenous
5x20mL
Not scheduled. Not considered by committee
INDICATIONS AS AT 30 April 2004: Treatment of severe hypophosphataemia (serum levels less than 0.3 mmol/L) and other degrees of hypophosphataemia when oral therapy is not possible. The cause of hypophosphataemia should be identified and treated.
Visual Identification: Clear colourless solution; Container Type: Ampoule; Container Life Time: 5 Years; Container Temperature: Store below 25 degrees Celsius
Registered
1991-10-08
DBL™ Sodium Phosphate and Potassium Phosphate Concentrated Injection Page 1 DBL™ SODIUM PHOSPHATE AND POTASSIUM PHOSPHATE CONCENTRATED INJECTION _ _ Sodium phosphate and potassium phosphate CONSUMER MEDICINE INFORMATION _Date of Dispensing _ _Consumer Name _ _Pharmacist Name _ _Consumer Address _ _Pharmacist Address _ _ _ WHAT IS IN THIS LEAFLET This leaflet answers some common questions about DBL™ Sodium Phosphate and Potassium Phosphate Injection. It does not contain all the available information. It does not take the place of talking to your doctor and pharmacist. All medicines have risks and benefits. Your doctor has weighed the risks of you being given DBL™ Sodium Phosphate and Potassium Phosphate Injection against the benefits this medicine is expected to have for you. IF YOU HAVE ANY CONCERNS ABOUT THIS MEDICINE, ASK YOUR DOCTOR OR PHARMACIST. KEEP THIS LEAFLET IN A SAFE PLACE. You may need to read it again. WHAT DBL™ SODIUM PHOSPHATE AND POTASSIUM PHOSPHATE INJECTION IS USED FOR DBL™ Sodium Phosphate and Potassium Phosphate Injection is a mixture of simple phosphate used to quickly increase the amount of phosphate in your body. Sodium phosphate and potassium phosphate work by providing a source of phosphate for your body to use. _ _ Your doctor may have prescribed this medicine for another reason. Ask your doctor if you have any questions about why Sodium Phosphate and Potassium Phosphate has been prescribed for you. This medicine is available only with a doctor’s prescription. DBL™ Sodium Phosphate and Potassium Phosphate Injection is not addictive._ _ BEFORE YOU ARE GIVEN DBL™ SODIUM PHOSPHATE AND POTASSIUM PHOSPHATE INJECTION _ _ _WHEN YOU MUST NOT BE _ _GIVEN IT _ YOU SHOULD NOT BE GIVEN SODIUM PHOSPHATE AND POTASSIUM PHOSPHATE IF: • THE PACKAGING IS TORN OR SHOWS SIGNS OF TAMPERING • THE EXPIRY DATE ON THE PACK HAS PASSED. If this medicine is used after the expiry date has passed, it may not work as well. • YOU HAVE ANY OF THE FOLLOWING MEDICAL CONDITIONS: • kidney disease Прочитајте комплетан документ
Version: pfpsodpi10619 Supersedes Version: 5.0 Page 1 of 8 AUSTRALIAN PRODUCT INFORMATION – DBL™ SODIUM PHOSPHATE AND POTASSIUM PHOSPHATE CONCENTRATED INJECTION 1. NAME OF THE MEDICINE Dibasic sodium phosphate dodecahydrate Monobasic potassium phosphate 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each 20 mL ampoule contains 3.840 g dibasic sodium phosphate dodecahydrate (Na 2 HPO 4 .12H 2 O) and 348 mg monobasic potassium phosohate (KH 2 PO 4 ) in Water for Injection. The pH of the solution ranges between 6.5 and 8.0. Each mL of injection contains 0.13 mmol (5 mg) of potassium ions, 1.07 mmol (24.6 mg) of sodium ions, 0.67 mmol (63 mg) of phosphate ions and 0.79 mmol (0.79 mg) of hydrogen ions. For the full list of excipients, see Section 6.1 List of excipients. 3. PHARMACEUTICAL FORM Dibasic sodium phosphate dodecahydrate appears as colourless, transparent, very efflorescent crystals. It is very soluble in water and practically insoluble in alcohol. Monobasic potassium phosohate is a white odourless granular or crystalline powder or colourless crystals. It is freely soluble in water and practically insoluble in alcohol. DBL™ Sodium Phosphate and Potassium Phosphate Concentrated Injection is a clear, colorless, sterile solution. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Treatment of severe hypophosphataemia (serum levels less than 0.3 mmol/L) and other degrees of hypophosphataemia when oral therapy is not possible. The cause of hypophosphataemia should be identified and treated. 4.2 DOSE AND METHOD OF ADMINISTRATION DOSAGE For the treatment of severe hypophosphataemia, the following doses are suggested: _Adults: _ up to 10 mmol phosphate administered over 12 hours. The dose may be repeated at 12 hour intervals _ _ until serum phosphate exceeds 0.3 mmol/L. Version: pfpsodpi10619 Supersedes Version: 5.0 Page 2 of 8 _Children: _ 0.15 to 0.33 mmol/kg administered over 6 hours. The dose may be repeated at 6 hour intervals until serum phosphate exceeds 0.6 mmol/L. The dose should not exceed the maximum Прочитајте комплетан документ